Transfer from high dose methadone to buprenorphine on a specialist in-patient unit – a case series



Dr Rebecca Lawrence, Ritson Clinic, Royal Edinburgh Hospital, Edinburgh EH10 5HF

November 2013

rebecca.lawrence@nhslothian.scot.nhs.uk


Background

Buprenorphine is the only licensed alternative to methadone in the UK for opioid replacement therapy. It carries less risk of respiratory depression and is safer in overdose. As it is a partial agonist, the withdrawal syndrome is often milder. Some patients are intolerant of methadone, find it stigmatising, or may be required to change due to drug interactions or prolonged QTc interval. Most current guidance advises a reduction in methadone to 30mg before transfer due to the risk of precipitated withdrawal, running a high risk of destabilisation.


Methods

Patients on methadone doses up to 120mg / day were admitted to the Ritson Clinic (specialist in-patient addictions unit) through their community addiction key workers. All gave written consent to be included in a prospective case series. Information recorded included diagnoses, comorbidity, use of alcohol and other drugs, length of time from stopping methadone to starting buprenorphine, COWS scores, dose of buprenorphine on discharge, total lofexidine required for symptomatic relief of withdrawals during the process, length of stay and perceived outcomes (patients and staff). Patients were encouraged to stop methadone just prior to admission, and were started on buprenorphine 4mg when showing clear opiate withdrawals signs (COWS ~ 15). One or two further 4mg doses were given on Day 1 depending on withdrawals, and patients were then titrated by up to 8mg daily until comfortable.

Recorded psychiatric comorbidities (past & present)




Results



15 patients were admitted from May 2012 to April 2013 and all successfully transferred to buprenorphine. Average time from stopping methadone to starting buprenorphine was 61.5 hours and average length of stay was 6.5 days.

Case	Dose of	Alcohol / illicit	Length of stav	Time from	COWS score	Dose on	Lofexidine	Outcome	Outcome
		drugs	(days)	stopping	prior to 1 st dose	discharge	received	(patient)	(staff)
1	65ml	Heroin 1 week ago; cannabis 3-4 weeks ago; occasional speed		48 hours	17	14mg	1.2mg	Good	Good
2	70ml (last had 35ml)	Cannabis	3	76 hours	16	12mg	0.4mg	Good	Good
3	50ml	Amphetamine; cannabis	9	48 hours	9	16mg	0.4mg	Good	Good
4	70ml	70ml methadone every 2 days; diazepam 2 x / month; occasional cannabis	e7	120 hours	15	16mg	None	Good	Good
5	120ml	Diazepam; methadone (?up to 100ml)	7	72 hours	12 (17 after 1st dose - ?precipitated withdrawal	24mg	2.4mg	Good	Good
6	45ml	None	6 days	32 hours	15	20mg	5mg	Reasonable	Reasonable
7	70ml	None	10 days	56 hours	13	24mg	2.8mg	Good	Good
8	70ml	Heroin (2 weeks prior); diazepam & "tablets"	_	121 hours	5	18mg	None	Good	Good
9	50ml	3 litres cider / day – also detoxed from alcohol; none (positive screen for benzodiazepine s couple weeks prior to admission)	·	51 hours	17	14mg	0.4mg	Good	Good
10	45ml	Intermittent diazepam & cannabis	4 days	54 hours	17	20mg	0.2mg	Better than expected	Good
11	115ml (last had 85ml)		10 days	56 hours	14	16mg	0.6mg	Very pleased	Good
12	100ml	Diazepam, heroin until 2 days prior to admission	7 days	48 hours	12	20mg	1.0mg	Good	Good
13	65ml (last had 30ml)	Occasional cannabis, alcohol, gabapentin & trazodone	2 days	19 hours	10	20mg	2.0mg	Better (early discharge due to personal circumstances)	Good
14	60ml	Heroin 1 week prior; cannabis	8 days	84 hours	20	20mg	2.0mg	Finding things difficult	Fair as regards withdrawals

Other psychotropic medication prescribed



Discussion and conclusions

These complex, and not always stable, patients all transferred from doses of between 45 and 120mg methadone. None were considered by staff to have precipitated withdrawal, and most perceived good outcomes and tolerated the process well. Most required high levels of support while waiting to go into opiate withdrawal and would have found this difficult in the community. Timings and final doses were highly variable, and not possible to predict. Clinical assessment of withdrawal was more helpful than COWS scores, and the author would suggest cautiously proceeding with initial buprenorphine dose (2-4mg) after 48 hours established abstinence from opiates in all patients. After the first dose, some clinicians titrate patients very rapidly to achieve stabilisation as quickly as possible; we proceeded more cautiously (maximum 8mg daily) to avoid higher than required ultimate dosing, which was possible with the increased support in this setting.

This series may help to inform further guidance in high dose transfers, depending on resources. Complex patients benefited from the high level of support available in an in-patient unit, but stable patients without comorbidities may well be transferred successfully in an out- or, preferably, day patient setting.

Bibliography

2007. Drug misuse and dependence: UK guidelines on clinical management

NICE (2007c), Methadone and buprenorphine for the management of opioid dependence: NICE technology appraisal guidance 114.